FDA
-
-
-
-
-
-
-
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
-
-
-
-
-
-
-
Cerecor to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
-
-
-
-
-
-
-
Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs
-
-
-
-
-
-
-
Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
-
-
-
-
-
-
-
Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
-
-
-
-
-
-
-
Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

